[go: up one dir, main page]

MX2023002953A - Inhibidores de proteína tirosina fosfatasa y métodos para su uso. - Google Patents

Inhibidores de proteína tirosina fosfatasa y métodos para su uso.

Info

Publication number
MX2023002953A
MX2023002953A MX2023002953A MX2023002953A MX2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
MX2023002953A
Other languages
English (en)
Inventor
Andrew Bogdan
Jennifer M Frost
Philip R Kym
Eric Voight
Zhaoming Xiong
Christos Economou
Elliot P Farney
Stacy Fosu
Spencer O Scholz
Original Assignee
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc filed Critical Calico Life Sciences Llc
Publication of MX2023002953A publication Critical patent/MX2023002953A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se proporcionan compuestos, que incluyen compuestos con la fórmula (I), composiciones y métodos útiles para la inhibición de la proteína tirosina fosfatasa, por ejemplo, la proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y/o la proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento de enfermedades, afecciones y trastornos relacionados que responden favorablemente al tratamiento con inhibidores de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
MX2023002953A 2020-09-11 2021-09-10 Inhibidores de proteína tirosina fosfatasa y métodos para su uso. MX2023002953A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077330P 2020-09-11 2020-09-11
PCT/US2021/049895 WO2022056281A1 (en) 2020-09-11 2021-09-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023002953A true MX2023002953A (es) 2023-06-01

Family

ID=78212618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002953A MX2023002953A (es) 2020-09-11 2021-09-10 Inhibidores de proteína tirosina fosfatasa y métodos para su uso.

Country Status (8)

Country Link
US (1) US20250122160A1 (es)
EP (1) EP4211122A1 (es)
JP (1) JP2023542503A (es)
CN (1) CN116829555A (es)
AU (1) AU2021342161A1 (es)
CA (1) CA3191842A1 (es)
MX (1) MX2023002953A (es)
WO (1) WO2022056281A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES
TW202345805A (zh) 2022-01-31 2023-12-01 美商必治妥美雅史谷比公司 蛋白酪胺酸磷酸酶抑制劑、其組合物及使用方法
US20250136564A1 (en) * 2022-02-02 2025-05-01 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
KR20250090365A (ko) * 2022-11-09 2025-06-19 브리스톨-마이어스 스큅 컴퍼니 암 질환의 치료를 위한 단백질 티로신 포스파타제 (ptpn2)의 억제제로서의 인다졸 치환된 1,2,5-티아디아졸리딘 유도체
WO2024138216A2 (en) * 2022-12-23 2024-06-27 Case Western Reserve University Compositions and methods for treating and detecting cancer
CN115819330A (zh) * 2022-12-28 2023-03-21 天津均凯农业科技有限公司 一种连续化制备2-氨基甲基-3-氯-5-三氟甲基吡啶的方法
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
WO2025011570A1 (zh) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
WO2025026158A1 (zh) * 2023-07-28 2025-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
TW202510846A (zh) * 2023-08-02 2025-03-16 美商耐瑞歐醫療公司 蛋白質酪胺酸磷酸酶降解劑及其用途
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
HK1211293A1 (en) * 2012-11-02 2016-05-20 辉瑞公司 Bruton's tyrosine kinase inhibitors
KR20250133466A (ko) * 2018-06-21 2025-09-05 칼리코 라이프 사이언시스 엘엘씨 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
PH12021552194A1 (en) * 2019-03-14 2022-08-22 Abbvie Inc Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CA3191842A1 (en) 2022-03-17
JP2023542503A (ja) 2023-10-10
AU2021342161A1 (en) 2023-05-25
AU2021342161A9 (en) 2024-02-08
US20250122160A1 (en) 2025-04-17
WO2022056281A1 (en) 2022-03-17
CN116829555A (zh) 2023-09-29
EP4211122A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
CL2024001723A1 (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
MX2024004318A (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso.
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CL2024001964A1 (es) Compuestos para la inhibición de nlrp3 y usos de estos
DOP2021000206A (es) Inhibidores de la proteína tirosina fosfatasa
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
MX2020013104A (es) Agentes activos y metodos de uso para el tratamiento de trastornos metabolicos y enfermedad hepatica no alcoholica.
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2024011736A2 (es) Inhibidores de proteína tirosina fosfatasa y usos de estos
CO2022014499A2 (es) Moduladores de nlrp3
CO2023016136A2 (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
CL2021000282A1 (es) Inhibidores de ckd8/19
UY38133A (es) Nuevos inhibidores de cdk8/19
MX2024012198A (es) Compuestos y metodos para tratar canceres
BR112022010672A2 (pt) Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica
MX2024012437A (es) Inhibidores de oxadiazol hdac6 y usos de estos
ECSP21042779A (es) Moduladores de la expresión de irf5